“From the earliest stages of development of our medicines, we are working to understand the needs of specific patients and the clinical impact our medicines will have.”

PETER MYRENFORS, Chief Medical Officer

Patient Stories (For US Consumers)

Ethan’s Story

Five-year-old Ethan has Hereditary Tyrosinemia Type 1 (HT-1). Like any family that has a child with this ultra-rare condition, the family have found Ethan’s diet and medication regime very demanding. Learn more about their journey.

Alina’s story

When Alina’s parents learned she had HT-1, they were understandably concerned. Watch their story.

For full Safety Information and Prescribing Information please visit:

NITYR® (nitisinone) Tablets are approved in the USA, Australia and the Kingdom of Saudi Arabia in 2, 5 and 10 mg strengths and in the EU and Chile in 10 mg strength. Cycle Pharmaceuticals’ nitisinone products are also approved under a different name, NITISINONE TABLETS, in Canada in 2, 5, and 10 mg strengths. Registration conditions differ internationally.

NITYR® is a registered trademark of Cycle Pharmaceuticals Limited in the United States.

To report an Adverse Event please click here.

PATIENT ADVOCACY
COMPASSIONATE USE